<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953054</url>
  </required_header>
  <id_info>
    <org_study_id>TPU-DMT-02-1503</org_study_id>
    <nct_id>NCT02953054</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Transdermal System (DMTS) for Post-Operative Analgesia Following Bunionectomy</brief_title>
  <acronym>DMTS</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Single-Dose Evaluation of the Dexmedetomidine Transdermal System for Post-Operative Analgesia Following Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teikoku Pharma USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Teikoku Pharma USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the DMTS, compared with a placebo patch,&#xD;
      will provide adequate pain relief during the first 3 days following bunionectomy surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the analgesic efficacy of the DMTS,&#xD;
      compared with placebo in subjects with acute moderate to severe pain following unilateral&#xD;
      bunionectomy.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To assess the safety and tolerability of the DMTS, including assessment of skin&#xD;
           irritation&#xD;
&#xD;
        -  To assess adhesion of the DMTS&#xD;
&#xD;
        -  To assess the sedation effect of the DMTS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2017</start_date>
  <completion_date type="Actual">July 3, 2017</completion_date>
  <primary_completion_date type="Actual">July 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-interval weighted summed pain intensity (SPI), measured using the 11 point (0 to 10) numeric rating scale (NRS) at designated time points from 4 to 24 hours following surgery (NRSSPI).</measure>
    <time_frame>From 4 to 24 hours following surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-interval weighted summed pain intensity over various time intervals</measure>
    <time_frame>Up to 72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects using opioid rescue pain medication</measure>
    <time_frame>Up to 72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to first use of rescue pain medication</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>DMTS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DMTS applied to the upper arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patches to match DMTS applied to the upper arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMTS</intervention_name>
    <description>DMTS applied before surgery and worn for 72 hours</description>
    <arm_group_label>DMTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching patches that have no active drug applied before surgery and worn for 72 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily provide written informed consent.&#xD;
&#xD;
          2. Male or female, â‰¥ 18 years of age.&#xD;
&#xD;
          3. Scheduled to undergo a primary unilateral first metatarsal bunionectomy repair.&#xD;
&#xD;
          4. Have a physical status classification of 1 or 2 per the American Society of&#xD;
             Anesthesiology.&#xD;
&#xD;
          5. Non-smoker for at least 1 year prior to screening; non-smoking is defined by cessation&#xD;
             of smoking and use of all other tobacco and nicotine products (including chewing&#xD;
             tobacco, snuff, e-cigarettes, nicotine patches, etc.).&#xD;
&#xD;
          6. Female subjects are eligible only if all the following apply:&#xD;
&#xD;
               1. Not pregnant, not lactating, and not planning to become pregnant during the study&#xD;
&#xD;
               2. Surgically sterile; or at least 2 years postmenopausal; or have a monogamous&#xD;
                  partner who is surgically sterile; or have a same gender sex partner; or is&#xD;
                  practicing double-barrier contraception; or practicing abstinence; or using an&#xD;
                  insertable, injectable, transdermal, or combination oral contraceptive&#xD;
&#xD;
          7. Male subjects with female sex partners must be surgically sterile or commit to the use&#xD;
             of a reliable method of birth control.&#xD;
&#xD;
          8. Have a body weight &gt; 50 kg, and body mass index of 22 to 38 kg/m2, inclusive.&#xD;
&#xD;
          9. Able to understand the study procedures, comply with all study procedures, and agree&#xD;
             to participate in the study program for its full duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a known sensitivity to dexmedetomidine or any excipient in the DMTS/placebo or to&#xD;
             any peri- or postoperative medication whose use is required in this study.&#xD;
&#xD;
          2. Have a skin abnormality (eg, scar, tattoo) or unhealthy skin condition (eg, burns,&#xD;
             wounds) at the patch application site, according to examination by the investigator at&#xD;
             screening or admission to the clinic prior to surgery.&#xD;
&#xD;
          3. Have a clinically significant abnormal clinical laboratory test value.&#xD;
&#xD;
          4. Have history of or positive test results for the human immunodeficiency virus (HIV),&#xD;
             hepatitis B, or hepatitis C.&#xD;
&#xD;
          5. Have a history or clinical manifestations of: a significant renal, hepatic,&#xD;
             cardiovascular, metabolic, neurologic, or psychiatric condition; congestive heart&#xD;
             failure, peptic ulcer, gastrointestinal bleeding, or other condition that would&#xD;
             preclude participation in the study.&#xD;
&#xD;
          6. Have a history of migraine or frequent headaches, seizures, or are currently taking&#xD;
             anticonvulsants.&#xD;
&#xD;
          7. Have another painful physical condition that may confound the assessments of&#xD;
             postoperative pain.&#xD;
&#xD;
          8. Have a history of syncope or other syncopal attacks.&#xD;
&#xD;
          9. Have evidence of a clinically significant 12-lead ECG abnormality.&#xD;
&#xD;
         10. Have a history of alcohol abuse or prescription/illicit drug abuse.&#xD;
&#xD;
         11. Have positive results on the urine drug screen or alcohol breath test indicative of&#xD;
             illicit drug or alcohol use at screening and/or clinic check-in.&#xD;
&#xD;
         12. Have a history or evidence of clinically significant orthostatic hypotension.&#xD;
&#xD;
         13. Have a resting heart rate of &lt; 50 beats per minute or systolic blood pressure &lt; 100&#xD;
             mmHg.&#xD;
&#xD;
         14. Have been receiving or have received opioid therapy chronically for &gt; 2 weeks within&#xD;
             the month prior to dosing of the study drug.&#xD;
&#xD;
         15. Use concurrent therapy that could interfere with the evaluation of efficacy or safety,&#xD;
             such as any drugs which in the investigator's opinion may exert significant analgesic&#xD;
             properties or act synergistically with dexmedetomidine.&#xD;
&#xD;
         16. Have had an upper respiratory tract infection within 14 days prior to dosing of the&#xD;
             study drug.&#xD;
&#xD;
         17. Have utilized oral or injectable corticosteroids within 14 days prior to dosing of the&#xD;
             study drug (intranasal and topical corticosteroid use during this time period is&#xD;
             allowed).&#xD;
&#xD;
         18. Have received any investigational product within 30 days prior to dosing of the study&#xD;
             drug.&#xD;
&#xD;
         19. Have previously received DMTS in a clinical trial.&#xD;
&#xD;
         20. Sensitivity to opioids, nonsteroidal anti-inflammatory drugs, or antibiotics.&#xD;
&#xD;
         21. In the opinion of the investigator or designee, is considered unsuitable for study&#xD;
             entry and/or is unlikely to comply with the study protocol for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Song, MS, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Teikoku Pharma USA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network LTD</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001 Jan;14(1):13-21.</citation>
    <PMID>16369581</PMID>
  </reference>
  <reference>
    <citation>KivistÃ¶ KT, Kallio A, Neuvonen PJ. Pharmacokinetics and pharmacodynamics of transdermal dexmedetomidine. Eur J Clin Pharmacol. 1994;46(4):345-9.</citation>
    <PMID>7957520</PMID>
  </reference>
  <reference>
    <citation>NÃ©methy M, Paroli L, Williams-Russo PG, Blanck TJ. Assessing sedation with regional anesthesia: inter-rater agreement on a modified Wilson sedation scale. Anesth Analg. 2002 Mar;94(3):723-8; table of contents.</citation>
    <PMID>11867405</PMID>
  </reference>
  <reference>
    <citation>American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030.</citation>
    <PMID>22227789</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Bunionectomy</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Transdermal</keyword>
  <keyword>Patch</keyword>
  <keyword>Postoperative</keyword>
  <keyword>DMTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

